Literature DB >> 17001173

Cyclopentenone: a special moiety for anticancer drug design.

Matteo Conti1.   

Abstract

The conjugate cyclopent-en-one chemical group is a special moiety for anticancer drugs. Studies on cyclopentenone prostaglandins, clavulones and other compounds have revealed its mechanism of action and a wide spectrum of intracellular targets, ranging from nuclear factors to mitochondria. The introduction of the cyclopentenone moiety into molecules, such as jasmonates and chalcones, has been shown to boost their anticancer potential. In this work, reviewing pertinent up-to-date literature, we have pointed out potentially effective cyclopentenone-bearing compounds for anticancer clinical research and inspiring relationships for future drug design. In particular, it appears that the addition of cyclopentenone groups to target-orienting molecules, in order to inactivate specific proteins in cells, could be a helpful general strategy for the development of novel therapeutic molecules.

Mesh:

Substances:

Year:  2006        PMID: 17001173     DOI: 10.1097/01.cad.0000231471.54288.00

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  8 in total

1.  (E)-3-(3-Bromo-phen-yl)-1-(4-methyl-phenyl)prop-2-en-1-one.

Authors:  Hongqi Li; B K Sarojini; C G D Raj; L N Madhu; H S Yathirajan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-10-31

2.  Methyl jasmonate decreases membrane fluidity and induces apoptosis through tumor necrosis factor receptor 1 in breast cancer cells.

Authors:  Laxmi Yeruva; John Abiodun Elegbede; Stephen W Carper
Journal:  Anticancer Drugs       Date:  2008-09       Impact factor: 2.248

3.  Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2.

Authors:  Ravindra Rajakariar; Mark Hilliard; Toby Lawrence; Seema Trivedi; Paul Colville-Nash; Geoff Bellingan; Desmond Fitzgerald; Muhammad M Yaqoob; Derek W Gilroy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-05       Impact factor: 11.205

4.  Mitochondrial targeting of the electrophilic lipid 15-deoxy-Delta12,14-prostaglandin J2 increases apoptotic efficacy via redox cell signalling mechanisms.

Authors:  Anne R Diers; Ashlee N Higdon; Karina C Ricart; Michelle S Johnson; Anupam Agarwal; Balaraman Kalyanaraman; Aimee Landar; Victor M Darley-Usmar
Journal:  Biochem J       Date:  2010-01-27       Impact factor: 3.857

Review 5.  Choline Chloride-Based DES as Solvents/Catalysts/Chemical Donors in Pharmaceutical Synthesis.

Authors:  Rosa Amoroso; Frank Hollmann; Cristina Maccallini
Journal:  Molecules       Date:  2021-10-18       Impact factor: 4.411

Review 6.  Jasmonate Compounds and Their Derivatives in the Regulation of the Neoplastic Processes.

Authors:  Iwona Jarocka-Karpowicz; Agnieszka Markowska
Journal:  Molecules       Date:  2021-05-13       Impact factor: 4.411

7.  Development and characterization of biocompatible isotropic and anisotropic oil-in-water colloidal dispersions as a new delivery system for methyl dihydrojasmonate antitumor drug.

Authors:  Gisela Bevilacqua Rolfsen Ferreira da Silva; Maria Virginia Scarpa; Gustavo Rossanezi; Eryvaldo Socrates Tabosa do Egito; Anselmo Gomes de Oliveira
Journal:  Int J Nanomedicine       Date:  2014-02-11

Review 8.  Cyclopentenone Prostaglandins: Biologically Active Lipid Mediators Targeting Inflammation.

Authors:  Bohae Rachel Lee; May Hnin Paing; Neelam Sharma-Walia
Journal:  Front Physiol       Date:  2021-07-15       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.